Press Releases

Date Title and Summary View
May 21, 2018 Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
Sesen Bio (Formally Eleven Biotherapeutics) Reports Positive, Three-Month Data from VISTA Trial of Vicinium™ in High-Grade NMIBC Data Presented During Plenary Session at American Urological Association Annual Meeting Company to Host Conference Call Today at 4:05 p.m. ET CAMBRIDGE, Mass.
View HTML
May 16, 2018 Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
Name Change Reflects Company’s Focus on Late-Stage Oncology Drug Development Appointments of Senior Medical Advisor and Vice President of Regulatory Affairs Strengthen Leadership Team as Company Prepares for Phase 3 Three-month NMIBC Data CAMBRIDGE, Mass.
View HTML
May 15, 2018 Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
Company to Host Conference Call in Conjunction with AUA Presentation on May 21, 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of
View HTML
April 12, 2018 New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 12, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that preclinical data from the company’s novel,
View HTML
April 4, 2018 Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to be Presented During Plenary Session at American Urological Association Annual Meeting; Company to Host Conference Call in Conjunction with Data Presentation in May 2018 Expected Operating Runway Extended into the First Quarter of 2019
View HTML
April 3, 2018 Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
Eleven Biotherapeutics to Host Conference Call in Conjunction with Data Presentation in May CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the
View HTML
March 21, 2018 Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that it has entered into a definitive agreement with several
View HTML
March 12, 2018 Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer
Eleven Biotherapeutics’ VISTA Trial of Vicinium™ in NMIBC On-Track for Topline Three-Month Data in Mid-2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 12, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies
View HTML
March 5, 2018 Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, president and chief executive
View HTML
February 8, 2018 Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive
View HTML